MBX

+ Watchlist + Portfolio

MBX Biosciences, Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $58.51
52-Week Range: $12.94 – $72.64
Market Cap: $2.81B
P/E (TTM): —
EPS (TTM): -2.37
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 6.82
PEG Ratio: —
Return on Equity: -33.17%
Return on Assets: -22.08%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 18.08
Debt/Equity: 0.01
Total Debt: $3.34M
Free Cash Flow: $-53.01M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $2.40B

MBX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$21.40M	$28.53M	$57.41M	$79.16M
Selling, General & Admin	$3.76M	$6.78M	$10.78M	$18.90M
Operating Expenses	$25.16M	$35.31M	$68.19M	$98.06M
Operating Income	-$25.16M	-$35.31M	-$68.19M	-$98.06M
EBITDA	-$25.70M	-$35.15M	-$67.95M	-$97.81M
Pretax Income	-$26.14M	-$32.56M	-$61.92M	-$86.97M
Net Income	-$26.14M	-$32.56M	-$61.92M	-$86.97M
Diluted EPS	-0.82	-1.02	-5.82	-2.38
Diluted Shares	31.85M	31.85M	10.64M	36.51M

MBX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$24.21M	$30.52M	$49.35M	$75.29M
Receivables	$142.00K	$208.00K	$682.00K	$2.12M
Current Assets	$44.21M	$83.47M	$267.29M	$381.54M
Total Assets	$45.09M	$84.18M	$268.54M	$385.14M
Current Liabilities	$3.43M	$3.93M	$11.05M	$15.49M
Total Debt	$461.00K	$324.00K	$171.00K	$596.00K
Total Liabilities	$87.70M	$156.65M	$11.09M	$15.92M
Retained Earnings	-$43.02M	-$75.58M	-$137.50M	-$224.48M
Shareholders' Equity	-$42.60M	-$72.47M	$257.44M	$369.22M
Working Capital	$40.78M	$79.54M	$256.24M	$366.04M

MBX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$23.12M	-$31.98M	-$54.68M	-$79.95M
Capital Expenditure	-$441.00K	-$129.00K	-$874.00K	-$1.93M
Free Cash Flow	-$23.56M	-$32.11M	-$55.55M	-$81.88M
Depreciation & Amortisation	$56.00K	$157.00K	$244.00K	$248.00K
Stock-Based Compensation	$306.00K	$2.04M	$5.22M	$8.68M
Investing Cash Flow	-$11.41M	-$30.93M	-$160.59M	-$83.70M
Financing Cash Flow	$46.06M	$69.22M	$234.10M	$189.59M
Net Change in Cash	$11.53M	$6.31M	$18.83M	$25.94M

MBX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$22.41M	$17.72M	$19.27M	$19.76M	$18.47M	$30.98M
Selling, General & Admin	$4.12M	$4.08M	$4.66M	$6.04M	$8.79M	$9.95M
Operating Expenses	$26.53M	$21.80M	$23.93M	$25.80M	$27.27M	$40.93M
Operating Income	-$26.53M	-$21.80M	-$23.93M	-$25.80M	-$27.27M	-$40.93M
EBITDA	-$26.45M	-$21.74M	-$23.88M	-$25.73M	-$27.20M	-$40.85M
Pretax Income	-$23.88M	-$19.41M	-$21.62M	-$22.06M	-$23.52M	-$37.09M
Net Income	-$23.88M	-$19.41M	-$21.62M	-$22.06M	-$23.52M	-$37.09M
Diluted EPS	-0.71	-0.58	-0.63	-0.49	-0.50	-0.78
Diluted Shares	33.41M	33.45M	34.20M	44.87M	46.58M	47.70M

MBX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$29.90M	$39.78M	$223.13M	$75.29M	$45.21M	$54.12M
Receivables	$1.39M	$841.00K	$1.55M	$2.12M	$3.16M	$3.04M
Current Assets	$244.28M	$229.19M	$397.50M	$381.54M	$448.54M	$427.86M
Total Assets	$245.93M	$231.52M	$400.08M	$385.14M	$452.70M	$435.91M
Current Liabilities	$10.48M	$11.76M	$12.06M	$15.49M	$14.57M	$23.66M
Total Debt	$130.00K	$650.00K	$623.00K	$596.00K	$555.00K	$3.34M
Total Liabilities	$10.50M	$12.28M	$12.54M	$15.92M	$14.95M	$26.37M
Retained Earnings	-$161.38M	-$180.80M	-$202.41M	-$224.48M	-$247.99M	-$285.09M
Shareholders' Equity	$235.42M	$219.24M	$387.54M	$369.22M	$437.76M	$409.54M
Working Capital	$233.79M	$217.43M	$385.44M	$366.04M	$433.97M	$404.20M

MBX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$22.68M	-$17.43M	-$21.54M	-$18.30M	-$20.21M	-$22.62M
Capital Expenditure	-$30.00K	-$707.00K	-$399.00K	-$793.00K	-$437.00K	-$901.00K
Free Cash Flow	-$22.71M	-$18.14M	-$21.93M	-$19.09M	-$20.64M	-$23.52M
Depreciation & Amortisation	$77.00K	$61.00K	$50.00K	$60.00K	$64.00K	$79.00K
Stock-Based Compensation	$1.84M	$1.94M	$2.25M	$2.66M	$5.48M	$6.06M
Investing Cash Flow	$3.23M	$25.99M	$17.06M	-$129.97M	-$97.10M	$29.21M
Financing Cash Flow	$4.00K	$1.33M	$187.82M	$438.00K	$87.44M	$2.32M
Net Change in Cash	-$19.45M	$9.88M	$183.34M	-$147.84M	-$29.87M	$8.91M

Market Snapshot

About

MBX Biosciences, Inc. is a clinical-stage precision endocrinology company developing peptide-based therapeutics for endocrine and metabolic disorders. The company focuses on diseases caused by hormonal imbalances, including hypoparathyroidism, post-bariatric hypoglycemia, and growth hormone deficiency. Their approach targets specific receptors to restore normal physiological function.